pde10

PDE10-IN-1 (SEP-0372814) is used for treating CNS and metabolic disorders.

PDE2 PDE10-IN-1 is an inhibitor of phosphodiesterase 2 (PDE2) and PDE10, with IC50 values of 29 nM and 480 nM, respectively.

PDE10-IN-5, a phosphodiesterase 10 (PDE10) inhibitor, is utilized for studying certain central nervous system disorders.

PDE10A-IN-8 is a potent inhibitor of PDE10A.

Compound 8a (PDE10A-IN-3) serves as an inhibitor of phosphodiesterase 10A (PDE10A) and is utilized in schizophrenia research [1].

Sp-cAMPS sodium salt is an analog of cAMP that serves as a potent activator of cAMP-dependent PKA I and PKA II, and as a competitive phosphodiesterase (PDE3A) inhibitor with a Ki of 47.6 μM. It also binds the PDE10 GAF domain with an EC50 of 40 μM [1] [2] [3].

BC 11-38 is a potent, selective PDE biodepressant which is mainly effective against PDE11 (IC50 : 0.28 μM).

Avanafil (TA1790) is a selective inhibitor of phosphodiesterase type 5 (PDE5) and is used as therapy of erectile dysfunction.

SEP-0372814 is a potent inhibitor of PDE10.

PDE5-IN-13 (Compound 14b) inhibits phosphodiesterase 5 (PDE5A) with an IC50 of 3 nM and is applicable in pulmonary arterial hypertension research. It demonstrates high selectivity for its target compared to PDE1, PDE2, PDE3, PDE4, PDE7, PDE8, PDE9, PDE10, and PDE11, and it possesses oral bioavailability.

PF-02545920, a PDE10 inhibitor, is used potentially for the treatment of Huntington's Disease.

Rp-cAMPS TEA salt is a cAMP-dependent protein kinase (PKA) activator.

AMG0074 is a PDE10 antagonist.

Avanafil dibesylate is a PDE5 inhibitor.

Sp-cAMPS triethylamine, a cAMP analog, serves as a potent activator of cAMP-dependent PKA I and II, and acts as a competitive inhibitor of phosphodiesterase (PDE3A) with a K i of 47.6 µM. Additionally, it binds the PDE10 GAF domain with an EC 50 of 40 μM [1] [2] [3].